Skip to content

Platform
- Overview
- Publications
Pipeline
About
Investors
Careers
Contact

Platform
- Overview
- Publications
Pipeline
About
Investors
Careers
Contact

Platform:
Publications

man working - Alto publications hero

Leveraging clinical and biological insights to drive innovation in psychiatry

See our publications, presentations, and more to discover the revolutionary potential of our precision approach.

Choose Resource Type
Choose Focus Area
Search Resources

Found 57 Results

June 30, 2025

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK

May 29, 2025

ALTO-300 as Adjunctive Treatment for Major Depressive Disorder Supported by Mechanistic Validation of Patient Selection Biomarker and Well-Established Safety and Tolerability Profile

April 28, 2025

Gamma Band EEG Sample Entropy, a Patient Selection Biomarker for ALTO-300 in MDD, is Increased by 5-HT2C Agonists in Mice

April 28, 2025

ALTO-203, a Novel Histamine H3 Inverse Agonist, Increase Sucrose Preference in Dopamine-depleted Rats

April 28, 2025

An EEG Biomarker for Predicting Placebo Response in Major Depressive Disorder: Development and Validation Across Open-Label and Double-Blind Trials

April 28, 2025

Translational Utility of ERP and Time-Frequency Features for Cognitive Impairment in Schizophrenia: Preclinical Evaluation of MK-801 Deficits and Rescue by ALTO-101

April 28, 2025

Gamma Band EEG Sample Entropy, a Patient Selection Biomarker for ALTO-300, is Increased by Dopamine Depletion in Humans and Mice

12 3 4 5...»

650 Castro Street, Suite 450
Mountain View, CA 94041

Company

About
Leadership
Careers
Contact

Science

Platform
Publications
Pipeline

Investors

Overview
News
Events & Presentations
Stock Info
SEC Filings
Corporate Governance
Resources

Privacy Notice
Terms of Use
Accessibility
Cookie Policy

© 2025 Alto Neuroscience Inc. All rights reserved.

Scroll to Top